USFDA Inspection at Jubilant HollisterStier General Partnership's Contract manufacturing facility at Montreal, Canada

Jubilant Pharmova Limited ('Company') today announced that Jubilant HollisterStier General Partnership ("JHSGP") has received a communication from the United States Food and Drug Administration (USFDA), through which the regulatory agency intimated that pursuant to its audit of JHSGP's contract manufacturing facility ("CMO") located at Montreal, Canada in the month of June'2024, it has determined the inspection classification of the facility as "Official Action Indicated" (OAI). The said audit was reported by the Company on 18 June 2024.

Since then JHSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures.

JHSGP is a subsidiary of Jubilant HollisterStier Inc., USA, a step down subsidiary of Jubilant Pharma Limited, Singapore, which is a wholly owned subsidiary of the Company.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 1151.90 as compared to the previous close of Rs. 1168.25. The total number of shares traded during the day was 12950 in over 888 trades.

The stock hit an intraday high of Rs. 1171.60 and intraday low of 1133.10. The net turnover during the day was Rs. 14937132.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 JubilantHollisterStierGeneralPartnership ContractManufacturingFacility Montreal Canada OAI Classification USFDA